Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD1 | P21728 | 2/20 | 0.33 |
| ▸ | SOD1 | P00441 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3154943 | 0.83 | DRD1 (0.35) | DRD1HSD17B10 | |
| SCHEMBL2497078 | 0.83 | DRD1 (0.49) | DRD1HSD17B10 | |
| SCHEMBL2800225 | 0.80 | ALDH1A3 (0.38) | DRD1HSD17B10 | |
| SCHEMBL3150400 | 0.75 | SOD1 (0.35) | DRD1SOD1CYP2C19HSD17B10 | |
| SCHEMBL6279527 | 0.74 | DRD1 (0.59) | DRD1 | |
| SCHEMBL11682199 | 0.73 | ALDH1A3 (0.38) | HSD17B10 | |
| SCHEMBL2800227 | 0.73 | MAPT (0.40) | SOD1CYP2C19HSD17B10 | |
| SCHEMBL3154935 | 0.71 | NOTUM (0.33) | HSD17B10 | |
| SCHEMBL2012634 | 0.70 | AHR (0.48) | — | |
| SCHEMBL29955117 | 0.70 | AHR (0.48) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7803954-B2 | Competitive and selective inhibitors of trypsin-like serine proteases involved in hemostasis; anticoagulants; Ph(3-Cl)(5-OCHF2) (R)CH(OH)C(O)-Aze-Pab(OMe); oral administration; gelling matrix modified-release system | ASTRAZENECA AB (SE) | 2010-09-28 | — | — | US | disclosed |
| EP-2186800-A1 | New mandelic acid derivatives and their use as thrombin inhibitors | Astra Zeneca AB (SE) | 2010-05-19 | — | — | EP | disclosed |
| US-20100087651-A1 | NEW MANDELIC ACID DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS | INGHARDT TORD | 2010-04-08 | — | — | US | disclosed |
| EP-1347955-B1 | NEW MANDELIC ACID DERIVATIVES AND THEIR USE AS THROBIN INHIBITORS | ASTRAZENECA AB (SE) | 2010-03-17 | — | — | EP | disclosed |
| US-7645751-B2 | Mandelic acid derivatives and their use as thrombin inhibitors | ASTRAZENECA (SE) | 2010-01-12 | — | — | US | disclosed |
| US-20080090800-A1 | Mandelic acid derivatives and their use as thrombin inhibitors | ASTRAZENECA AB | 2008-04-17 | — | — | US | disclosed |
| US-20070218136-A1 | New mandelic acid derivatives and their use as thrombin inhibitors | ASTRAZENECA AB | 2007-09-20 | — | — | US | disclosed |
| US-20070202174-A1 | New mandelic acid derivatives and their use as thrombin inhibitors | ASTRAZENECA AB | 2007-08-30 | — | — | US | disclosed |
| CN-1939903-A | Mandelic acid derivatives and their use as throbin inhibitors | ASTRAZENECA AB (SE) | 2007-04-04 | — | — | CN | disclosed |
| CN-1939902-A | Mandelic acid derivatives and their use as throbin inhibitors | ASTRAZENECA AB (SE) | 2007-04-04 | — | — | CN | disclosed |
| CN-1291975-C | Novel mandelic acid derivatives and their use as thrombin inhibitors | ASTRAZENECA AB (SE) | 2006-12-27 | — | — | CN | disclosed |
| US-7129233-B2 | Mandelic acid derivatives and their use as thrombin inhibitors | ASTRAZENECA AB (SE) | 2006-10-31 | — | — | US | disclosed |
| US-20060052314-A1 | Pharmaceutical combination | ASTRAZENECA AB (SE) | 2006-03-09 | — | — | US | disclosed |
| CN-1656066-A | combination drug | ASTRAZENECA AB (SE) | 2005-08-17 | — | — | CN | disclosed |
| EP-1513807-A1 | PHARMACEUTICAL COMBINATION | AstraZeneca AB (SE) | 2005-03-16 | — | — | EP | disclosed |
| CN-1487919-A | Novel mandelic acid derivatives and their use as thrombin inhibitors | — | 2004-04-07 | — | — | CN | disclosed |
| US-20040019033-A1 | Mandelic acid derivatives and their use as throbin inhibitors | ASTRAZENECA AB (SE) | 2004-01-29 | — | — | US | disclosed |
| WO-2003101956-A1 | PHARMACEUTICAL COMBINATION | ASTRAZENECA AB (SE) | 2003-12-11 | — | — | WO | disclosed |
| EP-1347955-A1 | NEW MANDELIC ACID DERIVATIVES AND THEIR USE AS THROBIN INHIBITORS | AstraZeneca AB (SE) | 2003-10-01 | — | — | EP | disclosed |
| WO-2002044145-A1 | NEW MANDELIC ACID DERIVATIVES AND THEIR USE AS THROBIN INHIBITORS | ASTRAZENECA AB (SE) | 2002-06-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090800-A1 | Mandelic acid derivatives and their use as thrombin inhibitors | TFPI, F2R, F2 | DRD1 3489/4885SOD1 2203/4885CYP2C19 99/4885 |
| US-20040019033-A1 | Mandelic acid derivatives and their use as throbin inhibitors | ADAMTS1, ADAMTS13, ADAMTS7 | DRD1 1225/4885SOD1 4721/4885CYP2C19 145/4885 |
| US-20100087651-A1 | NEW MANDELIC ACID DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS | TFPI, F2R, F2 | DRD1 3371/4885SOD1 2298/4885CYP2C19 137/4885 |
| US-20070202174-A1 | New mandelic acid derivatives and their use as thrombin inhibitors | TFPI, F2R, F2 | DRD1 3371/4885SOD1 2298/4885CYP2C19 137/4885 |
| US-20060052314-A1 | Pharmaceutical combination | F2, TNNT2, WFS1 | DRD1 569/4885SOD1 3808/4885CYP2C19 20/4885 |
| US-20070218136-A1 | New mandelic acid derivatives and their use as thrombin inhibitors | TFPI, F2R, F2 | DRD1 3371/4885SOD1 2298/4885CYP2C19 137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.